Match tier
Institution-verified
Presence
Current · Arkansas
Last published
2024
Sources
Institutional record
Refreshed
2026-10-05
P
Peter Anthony Crooks
Sourced from institutional research profiles (UAMS TRI or ARA).
◆ ARA Academy
High Impact
Drug research
Also affiliated: Southern Research Institute (1993); Northwestern University (2018); National Institute of Technology Warangal (2008–2015); Uppsala University (1993); University of London (1984); University of Minnesota (1988–1989); Kaiser Permanente (2008); University of Wisconsin–Madison (2013); University of Kentucky (1982–2024); Vanderbilt University (2011–2013); Washington University in St. Louis (2011); Trinity College Dublin (2024); University of Arkansas Medical Center (2013–2018); University of Arkansas System (2013–2018); Albert B. Chandler Hospital (1993–2007); Markey Cancer Center (2003); Hennepin County Medical Center (1988–1989); University of Manchester (1969–1989); University of Rochester Medicine (2008); Yale University (1978–1980); University of Florida (2009–2019); Indiana University Indianapolis (2008); Wake Forest University (2008); Belmont University (2013); University of Colorado Anschutz (2015); Cardiff University (2010); University of Birmingham (2010); Vanderbilt University Medical Center (2013); University of California, Berkeley (2013)
57 h-index
926 pubs
15,023 cited
Research Areas
Biomedical Subjects
Biography and Research Information
OverviewAI-generated summary
Peter A. Crooks is a researcher at the University of Arkansas for Medical Sciences, holding the Simmons Chair in Cancer Research and serving as Professor and Chairman of the Department of Pharmaceutical Sciences. His research career spans over forty years, with a focus on drug design and discovery, particularly in cancer-related research since the 1980s. He has authored over 560 publications and holds over 100 patents in drug discovery. His expertise includes prodrug and codrug design, drug metabolism, and pharmacokinetics, relevant to preclinical drug development. Crooks has been a founding member of seven drug discovery startup companies, and several of his discoveries have progressed to clinical trials. Notably, the anticancer drug Valchlor® was approved by the FDA for treating cutaneous T-cell lymphoma, with other drugs in development.
His scholarly contributions are reflected in a high-impact factor, with an h-index of 58 and over 15,000 citations from more than 930 publications. Crooks leads a research group and collaborates with researchers primarily within the University of Arkansas for Medical Sciences, including Narsimha Reddy Penthala and Meenakshisundaram Balasubramaniam. His recent publications indicate work on novel anti-leukemic agents, targeting aberrant glutathione metabolism, and exploring the mechanisms of action for compounds like parthenolide and lobeline. He has also investigated the anti-tumor activity of components from black seed (Nigella sativa L.) and the molecular pathways involved in cancer cell-cycle arrest and apoptosis.
Metrics
- h-index: 57
- Publications: 926
- Citations: 15,023
Positions
-
Drug research publications 2011–2024University of Arkansas for Medical Sciences Institutional directory
Selected Publications
-
Vesicular monoamine transporter-2 inhibitor JPC-141 prevents methamphetamine-induced dopamine toxicity and blocks methamphetamine self-administration in rats (2024)
-
Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan (2023)
-
High flux novel polymeric membrane for renal applications (2023)
-
Deuterated buprenorphine retains pharmacodynamic properties of buprenorphine and resists metabolism to the active metabolite norbuprenorphine in rats (2023)
-
Parthenolide induces rapid thiol oxidation that leads to ferroptosis in hepatocellular carcinoma cells (2022)
-
Characterizing the Access of Cholinergic Antagonists to Efferent Synapses in the Inner Ear (2021)
-
Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion (2021)
-
Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease (2021)
-
Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD) (2021)
-
Therapeutic Potentials of Selected Antihypertensive Agents and Their Fixed-Dose Combinations Against Trastuzumab-Mediated Cardiotoxicity (2021)
-
Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone (2021)
-
A pharmacokinetic study of <scp>morphine‐6‐<i>O</i></scp>‐sulfate in rat plasma and brain (2021)
-
Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs (2020)
-
Binding Modes and Selectivity of Cannabinoid 1 (CB1) and Cannabinoid 2 (CB2) Receptor Ligands (2020)
-
Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aβ Self-Aggregation and Metal Chelation-Induced Aβ Aggregation (2020)
ARA Academy 2011 ARA Scholar
Grants & Funding
As listed on this researcher's institutional profile.
- Development of Small Molecule Radiation Sensitizers NIH/Nat. Cancer Institute via Vanderbilt University
- Development of Novel Therapies for Methamphetamine Abuse NIH/Nat. Inst. on Drug Abuse via University of Kentucky Research Foundation
- Enhancing the prevention and treatment of orthopaedic infections associated with traumatic injury US Department of Defense
- Role of glucose transport in Alzheimer's disease pathogenesis NIH
- Use of precision deuteration to determine the contribution of norbuprenorphine to buprenorphine-associated neonatal abstinence syndrome NIH
- Covid-19 RAPID: Sprayable Cellulosic nanoparticle Coatings for COVID 19 Anti-viral Applications.
- Novel melampomagnolide B-based prodrugs for the treatment of leukemia NIH
- Functional optical biomarkers of response to therapy in head and neck squamous cell carcinoma- Resubmission Arkansas Economic Development Commission via National Science Foundation
- Early Events in Alzheimer Pathogenesis NIH
- Center for Studies of Host Response to Cancer Therapy NIH
- Development of Novel Therapeutics for Methamphetamine Abuse - Continuation NIH/Nat. Inst. on Drug Abuse via University of Kentucky Research Foundation
- Regulation of hepatic stellate cells by intracellular calcium NIH
- RII Track-1: Arkansas ASSET Initiative III - Continuation Y5 - Continuation National Science Foundation via Arkansas Economic Development Commission
- Role of glucose transport in Alzheimer’s disease pathogenesis NIH/Nat. Inst. on Aging
Collaboration Network
Top Collaborators
Narsimha Reddy Penthala
University of Arkansas for Medical Sciences
28 shared publications
In database
- Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents
- Synthesis and evaluation of a series of benzothiophene acrylonitrile analogs as anticancer agents
- Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4
- Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin
- Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs
Showing 5 of 28 shared publications
Meenakshisundaram Balasubramaniam
University of Arkansas for Medical Sciences
8 shared publications
In database
- MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells
- Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs
- A novel tetrazole analogue of resveratrol is a potent anticancer agent
- Aggregate Interactome Based on Protein Cross-linking Interfaces Predicts Drug Targets to Limit Aggregation in Neurodegenerative Diseases
- A Novel Microtubule-Binding Drug Attenuates and Reverses Protein Aggregation in Animal Models of Alzheimer’s Disease
Showing 5 of 8 shared publications
Robert L. Eoff
University of Arkansas for Medical Sciences
7 shared publications
In database
- Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents
- Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4
- Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin
- 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1)
- A Small-Molecule Inhibitor of Human DNA Polymerase η Potentiates the Effects of Cisplatin in Tumor Cells
Showing 5 of 7 shared publications
Venumadhav Janganati
University of Arkansas for Medical Sciences (US)
7 shared publications
- MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells
- Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin
- Synthesis and anti-proliferative activity of aromatic substituted 5-((1-benzyl-1H-indol-3-yl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione analogs against human tumor cell lines
- Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells
- Anti-cancer activity of carbamate derivatives of melampomagnolide B
Showing 5 of 7 shared publications
Craig T. Jordan
University of Colorado Anschutz Medical Campus (US)
6 shared publications
- Targeting Aberrant Glutathione Metabolism to Eradicate Human Acute Myelogenous Leukemia Cells
- MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells
- Rational Design of a Parthenolide-based Drug Regimen That Selectively Eradicates Acute Myelogenous Leukemia Stem Cells
- Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells
- Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells
Showing 5 of 6 shared publications
Michael J. Borrelli
University of Arkansas for Medical Sciences (US)
6 shared publications
- Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4
- Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells
- Actinomycin‐D and dimethylamino‐parthenolide synergism in treating human pancreatic cancer cells
- Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells
- Biobanked Glioblastoma Patient-Derived Organoids as a Precision Medicine Model to Study Inhibition of Invasion
Showing 5 of 6 shared publications
Robert J. Shmookler Reis
Central Arkansas Veterans Healthcare System
6 shared publications
In database
- Structural modeling of GSK3β implicates the inactive (DFG-out) conformation as the target bound by TDZD analogs
- Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aβ Self-Aggregation and Metal Chelation-Induced Aβ Aggregation
- Aggregate Interactome Based on Protein Cross-linking Interfaces Predicts Drug Targets to Limit Aggregation in Neurodegenerative Diseases
- A Novel Microtubule-Binding Drug Attenuates and Reverses Protein Aggregation in Animal Models of Alzheimer’s Disease
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
Showing 5 of 6 shared publications
Amit Ketkar
University of Arkansas for Medical Sciences
5 shared publications
In database
- Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4
- Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin
- 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1)
- A Small-Molecule Inhibitor of Human DNA Polymerase η Potentiates the Effects of Cisplatin in Tumor Cells
- N-Aroyl Indole Thiobarbituric Acids as Inhibitors of DNA Repair and Replication Stress Response Polymerases
Nikhil Reddy Madadi
University of Arkansas for Medical Sciences (US)
5 shared publications
- Synthesis and anti-cancer screening of novel heterocyclic-(2H)-1,2,3-triazoles as potential anti-cancer agents
- Synthesis and biological evaluation of novel 4,5-disubstituted 2H-1,2,3-triazoles as cis-constrained analogues of combretastatin A-4
- Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin
- Synthesis and anti-proliferative activity of aromatic substituted 5-((1-benzyl-1H-indol-3-yl)methylene)-1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione analogs against human tumor cell lines
- Anti-cancer activity of carbamate derivatives of melampomagnolide B
Poornima Bhat‐Nakshatri
Indiana University – Purdue University Indianapolis (US)
5 shared publications
- NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT
- Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells
- MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells
- Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
Harikrishna Nakshatri
Indiana University School of Medicine
5 shared publications
- NF-κB-dependent and -independent epigenetic modulation using the novel anti-cancer agent DMAPT
- Organ-specific adaptive signaling pathway activation in metastatic breast cancer cells
- MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells
- Pharmacological Dual Inhibition of Tumor and Tumor-Induced Functional Limitations in a Transgenic Model of Breast Cancer
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
Srinivas Ayyadevara
Central Arkansas Veterans Healthcare System
5 shared publications
In database
- Design and Synthesis of Novel Hybrid 8-Hydroxy Quinoline-Indole Derivatives as Inhibitors of Aβ Self-Aggregation and Metal Chelation-Induced Aβ Aggregation
- Aggregate Interactome Based on Protein Cross-linking Interfaces Predicts Drug Targets to Limit Aggregation in Neurodegenerative Diseases
- A Novel Microtubule-Binding Drug Attenuates and Reverses Protein Aggregation in Animal Models of Alzheimer’s Disease
- Novel hydroxybenzylamine-deoxyvasicinone hybrids as anticholinesterase therapeutics for Alzheimer’s disease
- Thiadiazolidinone (TDZD) Analogs Inhibit Aggregation-Mediated Pathology in Diverse Neurodegeneration Models, and Extend C. elegans Life- and Healthspan
Konjeti R. Sekhar
Vanderbilt University (US)
4 shared publications
- 1-Benzyl-2-methyl-3-indolylmethylene barbituric acid derivatives: Anti-cancer agents that target nucleophosmin 1 (NPM1)
- Targeting Nucleophosmin 1 Represents a Rational Strategy for Radiation Sensitization
- The Novel Chemical Entity YTR107 Inhibits Recruitment of Nucleophosmin to Sites of DNA Damage, Suppressing Repair of DNA Double-Strand Breaks and Enhancing Radiosensitization
- The NADH Oxidase ENOX1, a Critical Mediator of Endothelial Cell Radiosensitization, Is Crucial for Vascular Development
Jessica Ponder
University of Colorado Denver (US)
4 shared publications
- MMB triazole analogs are potent NF-κB inhibitors and anti-cancer agents against both hematological and solid tumor cells
- Dimers of Melampomagnolide B Exhibit Potent Anticancer Activity against Hematological and Solid Tumor Cells
- Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells
- Antitumor properties of novel sesquiterpene lactone analogs as NFκB inhibitors that bind to the IKKβ ubiquitin-like domain (ULD)
Shobanbabu Bommagani
University of Arkansas for Medical Sciences
4 shared publications
In database
- Synthesis and evaluation of a series of resveratrol analogues as potent anti-cancer agents that target tubulin
- A novel tetrazole analogue of resveratrol is a potent anticancer agent
- Indole carboxylic acid esters of melampomagnolide B are potent anticancer agents against both hematological and solid tumor cells
- Evaluation of bone and kidney toxicity of BT2-peg2, a potential carrier for the targeted delivery of antibiotics to bone
Similar Researchers
Based on overlapping research topics
Ashton Hale
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Hong-yu Li
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Pharmacological Effects and Toxicity Studies
Drug Transport and Resistance Mechanisms
Amal M. Shoeib
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Baku Acharya
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Hailey Kristian
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies
Amit Kumar Tiwari
University of Arkansas for Medical Sciences
Cancer Treatment and Pharmacology
Cancer-related molecular mechanisms research
Pharmacological Effects and Toxicity Studies